From models to molecules: Opioid receptor dimers, bivalent ligands, and selective opioid receptor probes

Journal of Medicinal Chemistry

Volumn 44, Issue 14, 2001, Pages 2259-2269

  Portoghese, P S ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CODEINE; DYNORPHIN A; G PROTEIN COUPLED RECEPTOR; KAPPA OPIATE RECEPTOR; LEUCINE ENKEPHALIN; LIGAND; METENKEPHALIN; MORPHINE; NALTRINDOLE; NORBINALTORPHIMINE; OPIATE; OPIATE ANTAGONIST; OPIATE RECEPTOR;

ARTICLE; BINDING SITE; DRUG POTENCY; HYDROPHOBICITY; LIGAND BINDING; LIPID BILAYER; MOLECULAR MODEL; MOLECULAR RECOGNITION; PROTEIN LOCALIZATION; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; BINDING SITES; DIMERIZATION; DYNORPHINS; LIGANDS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NALTREXONE; PROTEIN STRUCTURE, SECONDARY; RECEPTORS, OPIOID; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, KAPPA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0035811447     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm010158+     Document Type: Article

References (67)

1. The search for a better analgesic
2. Identification of two pentapeptides from brain with potent opiate agonist activity
3. Synthetic analgesics: Stereochemical considerations
4. Opioid peptides and opioid receptors
5. A potent and selective endogenous ligand for the μ-opiate receptor
6. A new concept on the mode of interaction of narcotic analgesics with receptors
7. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog
8. Endogenous opioid peptides: Multiple agonists and receptors
9. Internation union of pharmacology. XII. Classification of opioid receptors
10. Opiate (Enkephalin) receptors of neuroblastoma cells: Occurrence in clusters on the cell surface
11. Opioids and their complicated receptor complexes
12. Opioid agonist and antagonist bivalent ligands as receptor probes
13. Narcotic antagonist potency of bivalent ligands which contain β-naltrexamine. Evidence for bridging between proximal recognition sites
14. Opioid agonist and antagonist bivalent ligands. The relationship between spacer length and selectivity at multiple opioid receptors
15. Synthesis and opioid antagonist potencies of naltrexamine bivalent ligands with conformationally restricted spacers
16. Dimeric enkephalins display enhanced affinity and selectivity for the δ opiate receptor
17. Dimeric tetrapeptide enkepholins display extraordinary selectivity for the δ opiate receptor
18. Double enkephalins
19. Stereostructure-activity relationship of opioid agonist and antagonists ligands. Evidence for bridging between vicinal opioid receptors
20. Oligomerisation of G protein-coupled receptors
21. Domain swapping in G protein-coupled receptor dimers
22. Design and synthesis of naltrexone-derived affinity labels with nonequilibrium opioid agonist and antagonist activities. Evidence for the existence of different μ receptor subtypes in different tissues
23. Different receptor sites mediate opioid agonism and antagonism
24. Determination of the amino acid residue involved in [3H]β-funaltrexamine covalent binding in the cloned rat μ opioid receptor
25. G protein-coupled receptor heterodimerization modulates receptor function
26. Characterization of opioid receptors modulating neurogenic contractions of circular muscle from porcine ilieum and evidence that δ- and κ-opioid receptors are coexpressed in myenteric neurons
27. Methodone and heroin analgesia: μ changed to δ opioid receptor responses in methadone tolerant mice
28. Selective naltrexone-derived opioid receptor antagonists
29. Stereochemical studies on medicinal agents. 31. Only one pharacophore is required for the κ opioid antagonist selectivity of norbinaltorphimine
30. Structure-activity relationship of N17′-substituted norbinaltorphimine congeners. Role of the N17′ basic group in the interaction with a putative address subsite on the κ opioid receptor
31. Synthesis and κ-opioid antagonist selectivity of a norbinaltorphimine congener. Identification of the address moiety required for κ-antagonist activity
32. Role of the spacer in conferring κ opioid receptor selectivity to bivalent ligands related to norbinaltorphimine
33. Opioid antagonist activity of naltrexone-derived bivalent ligands: Importance of a properly oriented molecular scaffold to guide "address" recognition at κ opioid receptors
34. ACTH: A short introductory review
35. Analysis of selective binding epitopes for the κ-opioid receptor antagonist norbinaltorphimine
36. Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: Exploring the "address" recognition locus
37. Binding of norbenaltorphimine (norBNI) congeners to wild-type and mutant μ and κ opioid receptors: Molecular recognition loci for the pharmacophore and address components of κ antagonists
38. Mutational evidence for a common κ antagonist binding pocket in the wild-type κ and mutant μ [K303E] opioid receptors
39. Application of the message-address concept to the docking of naltrexone and selective naltrexone-derived opioid antagonists into opioid receptor models
40. Potent and selective indolomorphinan antagonists of the κ-opioid receptor
41. Transformation of a κ antagonist to a κ agonist by transfer of a guanidinium group from the 5′ to the 6′-position of naltrindole
42. Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin
43. 2 adrenoreceptor
44. 2 adrenergic receptor alters the orientation of its sixth membrane-spanning segment
45. Mutation of highly conserved aspartic acid in the β2 adrenergic receptor: Constitutive activation, structural instability and conformation rearrangement of transmembrane segment 6
46. Differential binding domains of peptide and non-peptide ligands in the cloned rat κ opioid receptor
47. Human κ opiate receptor second extracellular loop elevates dynorphin's affinity for μ/κ chimeras
48. Isosteric replacement of acidic with neutral residues in extracellular loop-2 of the κ-opioid receptor does not affect dynorphin A (1-13) affinity and function
49. Simulation of dynorphin A(1-10) binding to extracellular loop 2 of the κ-opioid receptor
50. Peptides as receptor modulators of opiate pharmacophores
51. Design of peptidomimetic δ opioid receptor antagonists using the message-address concept
52. Role of spacer and address components in peptidomimetic δ-opioid receptor antagonists related to naltrindole
53. Binaltorphimine-related bivalent ligands and their κ opioid receptor antagonist selectivity
54. Pyrrolomorphinans as δ opioid receptor antagonists. The role of steric hindrance in conferring selectivity
55. Discovery of a novel class of substituted pyrrolooctahy-droisoquinolines as potent and selective δ opioid agonists, based on an extension of the message-address concept
56. Synthesis of naltrexone-derived δ-opioid antagonists. Role of conformation of the δ address moiety
57. 1-opioid receptor antagonist: 7-benzylidene-naltrexone
58. 7-spiroindanyl derivatives of naltrexone and oxymorphone as selective ligands for δ opioid receptors
59. Differential antagonism of δ opioid agonist by naltrindole and its benzofuran analogue (NTB) in mice: Evidence for δ opioid receptor types
60. 6] Enkephalin and naltrindole 5′-isothiocyanate: evidence for δ receptor types
61. Bis-penicillamine enkephalins show pronounced δ receptor sensitivity
62. Analogues of μ-LPH61-64 possessing selective agonist activity at μ-opiate receptors
63. Deltorphins: A family of naturally occurring peptides with high affinity and selectivity for δ opioid binding sities
64. 1 agonists and antagonists
65. Structural requirements for specific recognition of μ or δ opiate receptors